Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study

Fineline Cube Jun 29, 2022

China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...

Company Drug

BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing

Fineline Cube Jun 29, 2022

Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...

Company Deals

MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO

Fineline Cube Jun 29, 2022

MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong...

Company Drug

Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease

Fineline Cube Jun 29, 2022

The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...

Company Drug

Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer

Fineline Cube Jun 29, 2022

China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...

Company Deals R&D

Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors

Fineline Cube Jun 29, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...

Company Deals

AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis

Fineline Cube Jun 29, 2022

Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement...

Company Drug

Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment

Fineline Cube Jun 29, 2022

China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...

Company Drug

Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management

Fineline Cube Jun 29, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...

Company Deals

LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline

Fineline Cube Jun 29, 2022

China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...

Company Deals

GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China

Fineline Cube Jun 29, 2022

China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to...

Company Deals

Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein

Fineline Cube Jun 29, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals...

Company R&D

Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU

Fineline Cube Jun 28, 2022

Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...

Company Deals

OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development

Fineline Cube Jun 28, 2022

Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement...

Company Deals

Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business

Fineline Cube Jun 28, 2022

Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million)...

Company Deals

Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development

Fineline Cube Jun 28, 2022

China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...

Company Drug

Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China

Fineline Cube Jun 28, 2022

The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...

Company Deals R&D

Hainan Lecheng Partners with Fosun Pharma on Innovative Medical Devices and Diagnostics

Fineline Cube Jun 28, 2022

The Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration has formed a partnership with...

Company Drug

Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines

Fineline Cube Jun 28, 2022

China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...

Company Drug

Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment

Fineline Cube Jun 28, 2022

US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...

Posts pagination

1 … 705 706 707 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.